Related Experiment Video
Updated: Sep 29, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
CALR-mutated myeloproliferative neoplasms: Refining molecular risk beyond the driver
1Department of Experimental and Clinical Medicine, Center for Research and Innovation of Myeloproliferative Neoplasms (CRIMM), AOU Careggi, University of Florence, Florence, Italy.
Abstract:
Calreticulin (CALR)-mutated myeloproliferative neoplasms (MPNs) are generally associated with favourable outcomes, yet considerable heterogeneity persists across the disease course. Mawalkar et al. provide long-term data across essential thrombocythaemia (ET), post-ET myelofibrosis (MF) and primary MF, highlighting the prognostic relevance of additional somatic mutations. The contribution of co-mutational context, variant allele frequency (VAF), disease origin and timing of molecular assessment remains incompletely defined. Commentary on: Mawalkar et al. Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms. Br J Haematol 2026 (Online ahead of print). doi: 10.1111/bjh.70859.
Related Concept Videos
Abnormal Proliferation
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
